2篇
您的检索式：作者名="Gordon B.Mills"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The PI3K/AKT Pathway and Renal Cell Carcinoma显示文摘The phosphatidylinositol 3 kinase(PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway,and thus is frequently activated as a cancer driver.More importantly,the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades,providing many potential targets for cancer therapy.Renal cell carcinoma(RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies.The PI3K/AKT pathway is modestly mutated but highly activated in RCC,representing a promising drug target.Indeed,PI3 K pathway inhibitors of the rapalog family are approved for use in RCC.Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC,reiterating the critical role of the PI3K/AKT pathway in this cancer.In this review,we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data,as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway. | Huifang Guo Peter German Shanshan Bai Sean Barnes Wei Guo Xiangjie Qi Hongxiang Lou Jiyong Liang Eric Jonasch Gordon B.Mills Zhiyong Ding | 2015 | Journal of Genetics and Genomics2015，42，7： | 39 |
| 2 | Profiling of immune features to predict immunotherapy efficacy显示文摘Immune checkpoint blockade(ICB)therapies exhibit substantial clinical benefit in different cancers,but relatively low response rates in the majority of patients highlight the need to understand mutual relationships among immune features.Here,we reveal overall positive correlations among immune checkpoints and immune cell populations.Clinically,patients benefiting from ICB exhibited increases for both immune stimulatory and inhibitory features after initiation of therapy,suggesting that the activation of the immune microenvironment might serve as the biomarker to predict immune response.As proof-of-concept,we demonstrated that the immune activation score(ISD)based on dynamic alteration of interleukins in patient plasma as early as two cycles(4-6 weeks)after starting immunotherapy can accurately predict immunotherapy efficacy.Our results reveal a systematic landscape of associations among immune features and provide a noninvasive,cost-effective,and time-efficient approach based on dynamic profiling of pre-and on-treatment plasma to predict immunotherapy efficacy. | Youqiong Ye Yongchang Zhang Nong Yang Qian Gao Xinyu Ding Xinwei Kuang Rujuan Bao Zhao Zhang Chaoyang Sun Bingying Zhou Li Wang Qingsong Hu Chunru Lin Jianjun Gao Yanyan Lou Steven HLin Lixia Diao Hong Liu Xiang Chen Gordon B.Mills Leng Han | 2022 | The Innovation2022，3，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员